Klinika Reuma Park Sp. z o.o. sp. k. | Centrum Medyczne Reuma Park

Research site

(Unclaimed)

Location

Aleja Wilanowska 333, Warsaw, Mazovia, Poland

Site insights

Top conditions

Top treatments

ESK-001

Ibuprofen

BMS-986165

MORF-057

LY3871801

Zasocitinib

Deucravacitinib

Paracetamol

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 8 total trials

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).The main aim of the s...

Enrolling

Psoriatic Arthritis

Drug: Active Comparator

Drug: Zasocitinib

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling

Systemic Lupus Erythematosus

Drug: Deucravacitinib

Other: Placebo

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (EMERALD-2)

This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 i...

Active, not recruiting

Colitis, Ulcerative

Inflammatory Bowel Diseases

Drug: MORF-057

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Active, not recruiting

Plaque Psoriasis

Drug: Placebo

Drug: Apremilast

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid...

Enrolling

Rheumatoid Arthritis

Drug: LY3871801

Drug: Placebo

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis (ONWARD3)

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling

Psoriasis

Severe Psoriasis

Drug: Open-Label ESK-001

Drug: Blinded ESK-001